Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-106b LNA knock-down probe
- Development stage
- Preclinical
- Lead developer
- Exiqon
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
miR-106b LNA knock-down probe is a synthetic antisense oligonucleotide incorporating Locked Nucleic Acid (LNA) modifications, designed to potently and specifically inhibit microRNA-106b (miR-106b). LNA technology involves a ribose modification that "locks" the sugar ring in a 3'-endo conformation, significantly increasing the stability and binding affinity of the probe to its complementary miRNA target. In oncology research, particularly concerning hepatocellular carcinoma (HCC), this probe is utilized to investigate the oncogenic role of miR-106b, which is frequently overexpressed in metastatic disease. By sequestering miR-106b, the probe facilitates the study of downstream pathways, such as the restoration of E-cadherin expression and the inhibition of the epithelial-mesenchymal transition (EMT), leading to reduced cell migration and invasion in preclinical models.
- Other names
- miR-106b LNA inhibitormiR106b LNA inhibitormiR 106b LNA inhibitoranti-miR-106b LNAanti-miR106b LNAanti-miR 106b LNALNA-antimiR-106bLNA-antimiR106bLNA-antimiR 106b
02
Targets
miR-106b-5p (MicroRNA 106b-5p)
Beyond the preview
Go deeper on miR-106b LNA knock-down probe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-106b LNA knock-down probe.